Last reviewed · How we verify

amoxicillin or moxifloxacin + rifampicin

Centre Hospitalier Universitaire de Nice · Phase 3 active Small molecule

amoxicillin or moxifloxacin + rifampicin is a Small molecule drug developed by Centre Hospitalier Universitaire de Nice. It is currently in Phase 3 development.

At a glance

Generic nameamoxicillin or moxifloxacin + rifampicin
SponsorCentre Hospitalier Universitaire de Nice
ModalitySmall molecule
PhasePhase 3

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about amoxicillin or moxifloxacin + rifampicin

What is amoxicillin or moxifloxacin + rifampicin?

amoxicillin or moxifloxacin + rifampicin is a Small molecule drug developed by Centre Hospitalier Universitaire de Nice.

Who makes amoxicillin or moxifloxacin + rifampicin?

amoxicillin or moxifloxacin + rifampicin is developed by Centre Hospitalier Universitaire de Nice (see full Centre Hospitalier Universitaire de Nice pipeline at /company/centre-hospitalier-universitaire-de-nice).

What development phase is amoxicillin or moxifloxacin + rifampicin in?

amoxicillin or moxifloxacin + rifampicin is in Phase 3.

Related